AMN Healthcare Services, Inc.

AMN Healthcare Services, Inc. (AMN) Market Cap

AMN Healthcare Services, Inc. has a market capitalization of $1.30B.

Price: $33.63

-1.08 (-3.11%)

Market Cap: 1.30B

NYSE · time unavailable

CEO: Caroline Sullivan Grace

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2001-11-13

Website: https://www.amnhealthcare.com

AMN Healthcare Services, Inc. (AMN) - Company Information

Market Cap: 1.30B|Sector: Healthcare

Company Profile

AMN Healthcare Services, Inc. (AMN) specializes in delivering comprehensive workforce solutions and staffing services to hospitals and healthcare facilities throughout the United States. Its operations are structured across three primary segments: The Nurse and Allied Solutions segment focuses on placing registered nurses in travel assignments, rapid response roles during emergencies or labor disruptions, and local positions. It also supplies allied health professionals for various roles and offers revenue cycle management solutions. Through its Physician and Leadership Solutions segment, AMN facilitates the placement of locum tenens physicians for temporary assignments, provides interim leadership for healthcare organizations, conducts executive searches, and handles permanent physician recruitment. Lastly, the Technology and Workforce Solutions segment encompasses services like language interpretation, vendor management systems (VMS), workforce optimization strategies, telehealth platforms, credentialing assistance, and various outsourced solutions. Beyond nurses and physicians, AMN's network of professionals includes a broad spectrum of allied health specialists such as physical, respiratory, and occupational therapists; medical and radiology technologists; lab technicians; speech pathologists; rehabilitation assistants; and pharmacists. The company leverages numerous recognized brands to deliver its services, including American Mobile, Nursefinders, NurseChoice, HealthSource Global Staffing, Onward Healthcare, O'Grady Peyton International, Med Travelers, Club Staffing, Staff Care, B.E. Smith, Merritt Hawkins, AMN Revenue Cycle Solutions, and AMN Language Services. Established in 1985, AMN Healthcare is headquartered in Dallas, Texas.

Analyst Sentiment

42%
Hold

From 9 Active Polls

1Y Forecast: $31.00

▼ -7.8% Potential Upside

Consensus Target Metrics

Low Bound

$26

Median

$29

High Bound

$40

Average

$31

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$31.00
▼ -7.82% Upside
Low Target
$26.00
-23% Risk
Median Target
$29.00
-14% Mid
High Target
$40.00
19% Max
Consensus
Buy
10 / 17 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1,3047136107487949379151,6191,883
Enterprise Value ($M)1,5219301,3801,5801,7081,9182,0022,7633,070
Price to Earnings Ratio (P/E)-39.102.87-19.706.37-1.71-214.56-1.2258.8828.67
Price/Earnings-to-Growth Ratio (PEG)0.03-1.10-0.18
Price to Sales Ratio (P/S)0.380.520.821.181.211.361.252.362.54
Price to Book Ratio (P/B)1.841.000.951.161.311.311.301.822.15
Price to Free Cash Flow Ratio (P/FCF)1.851.299.0350.6611.5511.3316.1734.1326.06
Enterprise Value to Sales (EV/Sales)0.671.842.492.602.782.734.024.15
Enterprise Value to EBITDA (EV/EBITDA)7.546.0830.4218.11-20.3836.64-12.4342.3137.25
Debt to Equity Ratio1.071.091.251.371.571.451.551.321.41

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 AMN HEALTHCARE INC (AMN) — Investment Overview

🧩 Business Model Overview

AMN HealthCare operates in healthcare workforce solutions, connecting healthcare providers (hospitals, health systems, clinics, and physician practices) with clinicians (nurses, allied health professionals, and certain physician-related roles). The firm sources candidates, handles credentialing and compliance requirements, matches supply to clinical demand, and then manages fulfillment through staffing placements or workforce management engagements.

The operating model creates customer “stickiness” through (1) procurement process integration—providers use AMN to streamline hiring for hard-to-fill roles, (2) credentialing and scheduling workflow embedded into provider operations, and (3) data-driven matching that reduces time-to-fill and operational friction for facilities.

💰 Revenue Streams & Monetisation Model

AMN’s revenue is primarily generated through staffing and workforce solutions contracts. Monetisation typically falls into two broad categories:

  • Transactional staffing revenue: billable placements where AMN earns a service margin between what providers pay and what clinicians are paid (net of benefits and related costs).
  • Workforce solutions / managed services revenue: engagements where AMN manages elements of labor procurement, staffing scheduling, or related services for provider organizations, typically with a more stable revenue profile and operating leverage from higher utilization and process standardization.

Margin drivers are largely behavioral and economic: the spread between bill rates and clinician compensation, clinician utilization (and replacement speed), contract mix, and the ability to control indirect costs (credentialing, compliance, and corporate overhead) per active placement.

🧠 Competitive Advantages & Market Positioning

AMN’s central moat is an integrated execution advantage reinforced by switching costs and network density.

  • Switching costs (operational workflow lock-in): Credentialing, onboarding, scheduling, and compliance create inertia. Providers that standardize on a workforce vendor reduce administrative burden and risk management overhead; replacing that workflow typically requires retraining and parallel onboarding processes.
  • High barriers to entry (credentialing and compliance): Healthcare staffing depends on meticulous licensing, background checks, and role-specific requirements. Scaling this correctly across geographies and specialties is operationally demanding and error-prone.
  • Network effects (candidate liquidity): A larger, higher-quality clinician network improves matching efficiency and fill rates, which improves provider outcomes and reinforces vendor preference.

Competitive benchmarking: AMN competes with other healthcare staffing and workforce solutions firms such as Aya Healthcare and Cross Country Healthcare, as well as large staffing alternatives like Jackson Healthcare (often operating with distinct branding and regional penetration).

While most competitors pursue similar end markets—demand for nurses and allied health professionals—AMN’s positioning emphasizes integrated workforce solutions alongside staffing, aiming to embed more deeply into provider labor management processes. This blend tends to make AMN less dependent on purely transactional staffing economics and more dependent on measurable service quality (time-to-fill, credentialing reliability, and scheduling performance).

🚀 Multi-Year Growth Drivers

The investment case over a 5–10 year horizon is supported by structural labor demand dynamics and the outsourcing trend in healthcare operations:

  • Chronic clinician shortages: Aging demographics, rising care complexity, and constrained training pipelines sustain demand for flexible staffing and supplemental labor.
  • Shift toward workforce flexibility: Hospitals and health systems increasingly value variable labor capacity to manage fluctuating patient volumes and care delivery patterns.
  • Vendor-managed labor procurement: Providers expand external labor management to reduce internal hiring friction, improve access to talent, and standardize contracting and credentialing.
  • Geographic and specialty breadth: Staffing demand varies by region and specialty; maintaining a broad clinician supply improves resilience and supports continued customer penetration.

⚠ Risk Factors to Monitor

  • Labor cost and bill-rate spread volatility: Staffing margins are sensitive to wage inflation, candidate availability, and pricing leverage with providers.
  • Provider utilization and reimbursement pressure: If hospital volumes soften or labor budgets tighten, demand for travel and supplemental staffing can compress.
  • Regulatory and compliance exposure: Licensing, employment classification, and credentialing requirements are complex. Errors can trigger financial penalties or operational disruption.
  • Concentration risk: Revenue can be exposed to specific health systems, contracts, or regions, particularly when customer procurement consolidates.
  • Technology disruption in matching and procurement: While staffing is still execution-heavy, customer procurement processes can shift toward alternative platforms or in-house systems that reduce reliance on staffing intermediaries.

📊 Valuation & Market View

Healthcare staffing companies are typically valued through revenue and operating profitability metrics, with EV/EBITDA and price-to-sales both used depending on growth and margin visibility. Key valuation sensitivities include:

  • Unit economics: the stability of the clinician cost vs. bill rate spread and utilization intensity.
  • Mix shift: a higher contribution from workforce solutions/managed services can improve predictability and operating leverage.
  • Operating discipline: how effectively the company scales credentialing and administrative functions as demand fluctuates.
  • Cash conversion: staffing businesses are exposed to working-capital dynamics driven by pay cycles and contract terms.

🔍 Investment Takeaway

AMN’s long-term value proposition rests on an execution-driven moat: deep credentialing/compliance capabilities, high clinician network density that improves fill rates, and workflow-level switching costs that anchor providers to the staffing and workforce management relationship. The secular backdrop—persistent clinician shortages and increased outsourcing of labor management—supports multi-year demand, while performance hinges on maintaining margin discipline through fluctuating labor markets.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for AMN.

defenseworld.net2026-07-30

Arrowstreet Capital Limited Partnership Boosts Stock Position in AMN Healthcare Services Inc $AMN

Arrowstreet Capital Limited Partnership grew its holdings in shares of AMN Healthcare Services Inc (NYSE: AMN) by 1,278.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,401,725 shares of the company's stock after purchasing an additional 1,300,005 shares

zacks.com2026-07-29

4 Value Stocks Investors Should Buy in the Second Half of 2026

PENN, CSV, GM and AMN emerge as late-2026 value picks, supported by attractive valuations, earnings growth and cash-flow strength.

zacks.com2026-07-28

AMN or RTO: Which Is the Better Value Stock Right Now?

Investors interested in Business - Services stocks are likely familiar with AMN Healthcare Services (AMN) and Rentokil Initial PLC (RTO). But which of these two stocks presents investors with the better value opportunity right now?

zacks.com2026-07-28

Are Business Services Stocks Lagging AMN Healthcare Services (AMN) This Year?

Here is how AMN Healthcare Services (AMN) and Dave Inc. (DAVE) have performed compared to their sector so far this year.

zacks.com2026-07-27

Here's Why AMN Healthcare Services (AMN) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com2026-07-24

AMN Healthcare Services (AMN) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

globenewswire.com2026-07-21

Smile Doctors Appoints Jeff Knudson as CFO to Help Scale Next Phase of Growth

DALLAS, July 21, 2026 (GLOBE NEWSWIRE) -- As demand for orthodontic care continues to rise—valued at approximately $22 billion in 2025 and projected to reach $26.9 billion by 2030—and Smile Doctors expands its national footprint, the organization today announced the appointment of Jeff Knudson as chief financial officer. An accomplished healthcare and multisite finance executive, Knudson will lead the company's financial strategy and finance organization.

zacks.com2026-07-10

Why AMN Healthcare Services (AMN) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

prnewswire.com2026-07-07

AMN Healthcare to Hold Second Quarter 2026 Earnings Conference Call on Thursday, August 6, 2026

DALLAS, July 7, 2026 /PRNewswire/ -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its second quarter 2026 financial results and third quarter 2026 outlook on Thursday, August 6, 2026, at 5:00 p.m. Eastern Time.

zacks.com2026-07-07

Here's Why You Should Retain AMN Stock in Your Portfolio for Now

AMN Healthcare's MSP momentum, labor disruption demand and AI-driven staffing tools support growth. But pricing pressure and industry shifts remain key risks.

zacks.com2026-07-06

Here's Why AMN Healthcare Services (AMN) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com2026-06-25

AMN Expands Workforce Intelligence Through Brightfield Alliance

AMN Healthcare's alliance with Brightfield boosts workforce intelligence, pairing TDX with analytics to support smarter healthcare labor planning.

fool.com2026-06-24

What This $114,000 AMN Healthcare Insider Sale Could Mean After a 41% Stock Gain

A director at AMN Healthcare Services reported selling 3,681 indirectly held shares for a total transaction value of approximately $114,000 on June 15, 2026. This represents 17% of Foletta's total holdings prior to the transaction, reducing indirect common stock ownership (via a trust) from 21,598 to 17,917 shares.

zacks.com2026-06-24

Here's Why AMN Healthcare Services (AMN) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

prnewswire.com2026-06-24

AMN Healthcare and Brightfield Launch First-of-its-Kind Healthcare Partnership Advancing Workforce Intelligence and Market Transparency

Strategic collaboration expands AMN's healthcare workforce intelligence with broader and enriched market data to help healthcare organizations make smarter, faster, and more confident labor decisions DALLAS, June 24, 2026 /PRNewswire/ -- AMN Healthcare, the leader and innovator in healthcare total talent solutions, today announced it is expanding its workforce intelligence capabilities through a strategic partnership with Brightfield, a leader in measurable workforce intelligence, to deliver enhanced market intelligence and greater transparency to healthcare organizations. Brightfield's Talent Data Exchange, or TDX, adds third-party market data and validation to AMN's proprietary healthcare workforce insights.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"AMN reported Q1’26 revenue of $1.378B and net income of $62.2M (EPS $1.60), turning profitable versus the prior quarter and materially improving year over year. QoQ, revenue rose from $748.2M in Q4’25 to $1.378B (+84.1%), while net income improved from -$7.7M to +$62.2M (an $69.9M swing). YoY, revenue increased from $689.5M in Q1’25 to $1.378B (+100.0%), and net income moved from -$1.1M to +$62.2M (>$63M improvement). Profitability strengthened across the quarter set: Q1’26 gross margin was 26.8% versus 21.4% in Q4’25 and 28.7% in Q1’25, while net margin expanded sharply to 4.5% from -1.0% in Q4’25 and from ~-0.2% in Q1’25. Operating income and EPS also surged (operating income ratio 8.5% in Q1’26 vs 1.1% in Q4’25). Cash flow quality was strong in Q1’26 with operating cash flow of $562M and free cash flow of $562M; leverage looks improved on the quarter (cash jumped to $560.7M and equity reached $712.8M, versus -$567.7M in Q4’25). There were no dividends paid or share repurchases indicated in Q1’26 cash flow. Total shareholder returns appear supported by price momentum (1Y change +10.81%), but it was below the >20% threshold. Analyst targets (consensus ~$22.5) are above the current price ($20.19), implying upside."

Revenue Growth

Strong

Revenue accelerated sharply: +84.1% QoQ (Q4’25 $748.2M to Q1’26 $1.378B) and +100.0% YoY (Q1’25 $689.5M to Q1’26 $1.378B).

Profitability

Good

Net margin expanded to 4.5% in Q1’26 from -1.0% in Q4’25 and roughly -0.2% in Q1’25. EPS improved to $1.60 from -$0.20 (QoQ) and -$0.03 (YoY). Margins are clearly recovering QoQ, though gross margin is slightly below Q1’25 (26.8% vs 28.7%).

Cash Flow Quality

Positive

Q1’26 operating cash flow was $562M and free cash flow was $562M, strongly supporting earnings quality. However, no dividends or buybacks are shown in Q1’26, limiting direct shareholder yield.

Leverage & Balance Sheet

Neutral

Balance sheet resilience improved materially QoQ: cash increased to $560.7M (from $33.97M) and total equity turned positive at $712.8M (from -$567.7M in Q4’25). Long-term debt was $742.5M, while net debt fell to $181.8M from $769.2M.

Shareholder Returns

Neutral

Price return looks constructive but not exceptional: +10.81% over 1Y, with no dividend yield (0%). No buyback activity is indicated in Q1’26 cash flow.

Analyst Sentiment & Valuation

Good

Street consensus target ($22.5) is above the current price ($20.19), suggesting positive implied upside. Current valuation metrics (e.g., P/E ~2.87 on provided ratios) also appear favorable given the earnings rebound.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

AMN’s Q1 2026 beat is heavily shaped by labor disruption execution ($722M revenue) and rapid response mix, lifting revenue and profitability despite underlying macro softness signals. Consolidated revenue was $1.38B and gross margin 26.8%, though margins were still down 190 bps YoY. Management highlighted that, excluding labor disruption travelers, Nurse & Allied reached YoY volume growth for the first time since 2022—an important normalization milestone—supported by higher bill rates (+6% YoY) and international rebound. The key forward swing factor is bill-rate normalization: Q2 Nurse & Allied revenue is guided flat-to-down 2% YoY with bill-rate normalization, and Q2 Physician & Leadership remains pressured (down ~6% to 8% YoY) due to locums softness, competitive channels, and reserve/mix drag. Technology & Workforce trends show early language-service margin progress but continued top-line decline. International growth depends on embassy-stage visa throughput; management expects high-teens YoY in 2026 with upside only if approvals accelerate.

AI IconGrowth Catalysts

  • Labor disruption execution: supported 5 events in Q1 (3 large; 2 of 3 indefinite), enabling rapid clinician deployment at higher bill rates
  • Nurse & Allied normalization excluding labor disruption: nurse and allied traveler volume grew YoY excluding labor disruption travelers for the first time since 2022
  • Rapid response placement mix: average bill rate up 6% YoY driven by surge in rapid response placements
  • International staffing rebound: international staffing revenue grew 17% QoQ and returned to YoY growth for the first time since Q4 2023
  • WorkWise AI deployment: deployed AI recruiter to move 10,000+ clinicians in Q1 and rolled out automation (automated candidate scoring, improved search across open orders/available staff, easier job descriptions)
  • Language services model: tiered service/pricing rollout with early progress in new sales wins and gross margin improvement

Business Development

  • International growth linked to Visa retrogression improvement (State Department) reducing constraints on candidate approvals
  • Locums: added a new locum MSP client during the quarter and renewed/expanded contracts with largest locums clients
  • Technology: WorkWise supplier performance analytics adoption mentioned (client transparency into supplier quality/responsiveness/outcomes)
  • Corporate actions referenced: Smart Square sold/divested July 2025 (used as an ongoing YoY comparison adjustment)

AI IconFinancial Highlights

  • Revenue: $1.38B in Q1, above both guidance range and consensus; Q1 guidance exceeded by ~$122M from labor disruption revenue
  • Gross margin: 26.8% in Q1, above high end of guidance; YoY down 190 bps and sequentially up 70 bps
  • Adjusted EBITDA: $166M, 12.1% margin; up 280 bps YoY and 480 bps sequentially (labor disruption and rapid response mix cited)
  • Segment margins: Nurse & Allied gross margin 25.1% (+240 bps YoY; +350 bps sequential); Physician & Leadership gross margin 26.1% (-120 bps YoY; -140 bps sequential) driven by locums margin drag and +110 bps sales reserves
  • Physician & Leadership volume: locum tenens revenue down 9% volume YoY; revenue per day filled up 3%; Q1 Physician & Leadership revenue -6% YoY
  • Technology & Workforce: revenue $87M (-15% YoY; -10% YoY excluding Smart Square divest), gross margin 50% (-550 bps YoY; +190 bps sequential with ~200 bps language services improvement)
  • Cash/deposits: ended Q1 with $551M cash; client deposits $367M with ~$250M refunded in Q1/Q2 window (management expects ~$175M cash at quarter end if remaining deposits repaid this quarter)
  • Working capital: DSO 26 days; excluding labor disruption working capital effects DSO 54 days (-4 days YoY; -2 days sequential)

AI IconCapital Funding

  • Revolver: paid down revolver in Q1; leverage ratio reduced to 1.6x at quarter end
  • Cash runway/deposits: excess client deposits from labor disruption events drove cash build; management indicated remaining deposits repayment could leave ~$175M cash at quarter end (subject to timing)
  • Debt: total debt $750M as of Q1 end
  • Buyback: not mentioned in transcript

AI IconStrategy & Ops

  • Technology enablement: event management system and AI recruitment used to coordinate/comply/execute at scale during labor disruption
  • WorkWise automation: automated candidate scoring; improved search across open orders and available staff; job description creation workflow; supplier performance analytics
  • AMN Passport adoption: Passport users +30% YoY; monthly active users +50% YoY; Passport feature additions over the past year
  • Locums recruiting automation: initiatives to tech enable/automate recruiting and add recruiters to increase speed/fill rates in competitive third-party channel
  • Go-to-market refresh: refreshed approaches for executive/leadership search and interim to align with client needs (C-suite turnover, digitally fluid/data-driven leaders, workforce strategy)
  • International delivery: continued onboarding and approval pipeline progression constrained by visa retrogression timing; management expects high-teens YoY international growth in 2026

AI IconMarket Outlook

  • Q2 consolidated revenue guide: $620M to $635M
  • Q2 gross margin guide: 28.0% to 28.5%
  • Q2 SG&A guide: ~23.0% to 23.5% of revenue (cost discipline + growth investments)
  • Q2 operating margin guide: -0.6% to +0.1%
  • Q2 adjusted EBITDA margin guide: 6.7% to 7.2%
  • Q2 Nurse & Allied Solutions revenue guide: flat to down 2% YoY including normalization of segment bill rate
  • Q2 Physician & Leadership Solutions revenue guide: down ~6% to 8% YoY
  • Q2 Technology & Workforce Solutions revenue guide: down ~14% to 16% YoY (improved sequential trend expected)
  • International growth expectation: high teens YoY for 2026; potential low double-digit growth into 2027 with embassy-stage timing variability

AI IconRisks & Headwinds

  • Gross margin pressure drivers: YoY gross margin down 190 bps; Physician & Leadership margin drag from locums mix and +110 bps sales reserves; Technology & Workforce margin down 550 bps YoY due to pricing pressure and unfavorable mix
  • Locums demand softer: more demand in third-party channel (more competitive/harder to fill); lower fill rates offset MSP progress
  • Nurse demand muted: underlying nurse demand described as muted though improving to flat YoY recently
  • Bill rate normalization risk: rapid response bill rate elevation not expected to recur in Q2; management explicitly expects bill rate normalization
  • International execution depends on visa approval throughput: candidates progressing through embassy approval; management does not assume travel ban/suspension tailwinds

Q&A: Analyst Interest

  • Topic: Rapid response vs labor disruption mechanics and margin implications: Management explained rapid response orders are shorter-duration with faster deployment needs and typically higher bill rates/payouts; however, it’s not viewed as a dominant margin driver. Management emphasized mix elevated Q1 bill rate and expects normalization in Q2.
  • Topic: Q2 gross margin bridge and labor disruption revenue embedded: Management said Q1 gross margin was 26.8% with drag from physician/lower margin sales adjustments and one-time items. For Q2, midpoint guidance 28.2% includes ~$10M labor disruption revenue and some flow-through from reconciled prior events; normalized gross margin expected closer to ~27.5%.
  • Topic: International outlook under Visa retrogression updates: Management reiterated high-teens YoY international growth for 2026, with improvement in retrogression dates but candidates now in embassy approval. They said no significant acceleration assumed. Any upside would likely appear late 2026 and support low-double-digit growth into 2027 if embassy approvals advance faster.

Sentiment: MIXED

Note: This summary was synthesized by AI from the AMN Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for AMN.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (AMN)

© 2026 Stock Market Info — AMN Healthcare Services, Inc. (AMN) Financial Profile